GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Change In Inventory

NeoGenomics (NeoGenomics) Change In Inventory : $3.6 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Change In Inventory?

NeoGenomics's change in inventory for the quarter that ended in Mar. 2024 was $3.8 Mil. It means NeoGenomics's inventory declined by $3.8 Mil from Dec. 2023 to Mar. 2024 .

NeoGenomics's change in inventory for the fiscal year that ended in Dec. 2023 was $-0.5 Mil. It means NeoGenomics's inventory increased by $0.5 Mil from Dec. 2022 to Dec. 2023 .

NeoGenomics's Total Inventories for the quarter that ended in Mar. 2024 was $20.3 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. NeoGenomics's Days Inventory for the quarter that ended in Mar. 2024 was 22.36.

Inventory Turnover measures how fast the company turns over its inventory within a year. NeoGenomics's Inventory Turnover for the quarter that ended in Mar. 2024 was 4.08.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NeoGenomics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.14.


NeoGenomics Change In Inventory Historical Data

The historical data trend for NeoGenomics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Change In Inventory Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.75 -15.20 1.63 -1.10 -0.45

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.69 0.64 -0.20 3.84

NeoGenomics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeoGenomics  (NAS:NEO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NeoGenomics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=22.238/90.771*365 / 4
=22.36

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

NeoGenomics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NeoGenomics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeoGenomics Change In Inventory Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913